Tri Locum Partners’s Definium Therapeutics DFTX Stock Holding History

Tri Locum Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.67M	Sell	162,996 -206,592	-56%	-$5.11M	0.94%	19
2026 Q1	$6.99M	Buy	+369,588	New	+$6.27M	0.98%	17
2025 Q1	–	Sell	-820,793	Closed	-$5.71M	–	32
2024 Q4	$5.71M	Sell	820,793 -842,160	-51%	-$5.79M	1.18%	23
2024 Q3	$9.46M	Buy	1,662,953 +1,280,898	+335%	+$8.91M	2.27%	15
2024 Q2	$2.75M	Buy	382,055 +2,459	+0.6%	+$21.5K	0.7%	23
2024 Q1	$3.57M	Buy	+379,596	New	+$2.16M	1.24%	25

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Tri Locum Partners's DFTX Position: Q2 2026 in Review

Tri Locum Partners reduced its Definium Therapeutics (DFTX) stake by 56% in Q2 2026, selling an estimated $5.11M and leaving 162,996 shares worth $7.67M. The position accounts for 0.94% of the portfolio, ranked #19.

Tri Locum Partners first reported a position in DFTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $9.46M in Q3 2024. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Tri Locum Partners held 162,996 shares of Definium Therapeutics worth $7.67M as of Q2 2026.
Tri Locum Partners sold 206,592 Definium Therapeutics shares in Q2 2026, an estimated $5.11M.
Definium Therapeutics made up 0.94% of Tri Locum Partners's portfolio in Q2 2026, its #19 holding.
Tri Locum Partners first reported a position in Definium Therapeutics in Q1 2024 and has held it in 6 quarters since.
Tri Locum Partners's Definium Therapeutics position peaked at $9.46M in Q3 2024.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.